Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy

References

• Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92(4):289–297.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Barbui T. Polycythaemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90(2):162–173.
   PubMed Web of Science ®Google Scholar
• Gugliotta L, Marchioli R, Fiacchinni M, et al. Epidemiological, diagnostic, therapeutic, and prognostic aspects of essential thrombocythemia in a retrospective study of the GIMMC group in two thousand patients. Blood. 1997;90. 348a(suppl 1, abstr).
   Web of Science ®Google Scholar
• Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874–1881.
   PubMed Web of Science ®Google Scholar
• Harrison CN. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol. 2005;129:293–306. .
   PubMed Web of Science ®Google Scholar
• Griesshammer M, Struve S, Barbui T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev. 2008;22(5):235–245.
   PubMed Web of Science ®Google Scholar
• Lavi N, Brenner B, Avivi I. Management of pregnant women with myeloproliferative neoplasms. Thromb Res. 2013;131:S11–S13.
   PubMed Web of Science ®Google Scholar
• Alimam S, Bewley S, Chappell LC, et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol. 2016;175:31–36.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukaemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Bates SM, Ginsberg JS. Thrombosis in pregnancy. Curr Opin Hematol. 1997;4:335–343.
   PubMedGoogle Scholar
• Nelson SM, Greer IA. Thrombophilia and the risk for venous thromboembolism during pregnancy, delivery, and puerperium. Obstet Gynecol Clin N Am. 2006;33:413–427.
   PubMed Web of Science ®Google Scholar
• Richter R, Bergmann RL, Dudenhausen JW. Previous caesarean or vaginal delivery: which mode is a greater risk of perinatal death at the second delivery? Eur J Obstet Gynecol Reprod Biol. 2006;132:51–57.
   PubMed Web of Science ®Google Scholar
• Griesshammer M, Heimpel H, Tc P. Essential thrombocythemia and pregnancy. Leuk Lymphoma. 1996;22(Suppl 1):57–63.
   PubMed Web of Science ®Google Scholar
• Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol. 2001;66(3):152–159. .
   PubMed Web of Science ®Google Scholar
• Elliott MA, Tefferi A. Thrombocythemia and pregnancy. Best Pract Res Clin Haematol. 2003;16:227–242.
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematolo. 2004;89(2):215–232.
   PubMed Web of Science ®Google Scholar
• Niittyvuopio R, Juvonen E, Kaaja R, et al. Pregnancy in essential thrombocythaemia: experience with 40 pregnancies. Eur J Haematol. 2004;73(6):431–436.
   PubMed Web of Science ®Google Scholar
• Griesshammer M, Struve S, Harrison CM. Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe. Semin Thromb Hemost. 2006;32:422–429.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood. 2007;110(2):485–489.
   PubMed Web of Science ®Google Scholar
• Melillo L, Tieghi A, Candoni A, et al. Outcome of 122 pregnancies in essential thrombocythemia patients: a report from the Italian registry. Am J of Hematol. 2009;84:636–640.
   PubMed Web of Science ®Google Scholar
• Gangat N, Wolanskyj AP, Schwager S, et al. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. Eur J Haematol. 2009;82:350–353.
   PubMed Web of Science ®Google Scholar
• Randi ML, Bertozzi I, Rumi E, et al. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. Am J Hematol. 2014;89:306–309.
   PubMed Web of Science ®Google Scholar
• Rumi E, Bertozzi I, Cassetti IC, et al. Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia. Haematologica. 2015;100(11):e443–e445.
   PubMed Web of Science ®Google Scholar
• Cincotta R, Higgins JR, Tippett C, et al. Management of essential thrombocythaemia during pregnancy. Aust N Z J Obstet Gynaecol. 2000;40:33–37.
   PubMed Web of Science ®Google Scholar
• Palandri F, Polverelli N, Ottaviani E, et al. Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. Haematologica. 2010;95:1038–1040.
   PubMed Web of Science ®Google Scholar
• Umazume T, Yamada T, Akaishi R, et al. Essential thrombocythemia as a risk factor for stillbirth. Thromb Res. 2014;133:158–161.
   PubMed Web of Science ®Google Scholar
• Robinson S, Bewley S, Hunt BJ, et al. The management and outcome of 18 pregnancies in women with polycythemia vera. Haematologica. 2005;90(11):1477–1483.
   PubMed Web of Science ®Google Scholar
• Aggarwal N, Chopra S, Suri V, et al. Polycythemia vera and pregnancy: experience of four pregnancies in a single patient. Arch Gynecol Obstet. 2011;283(2):393–395.
   PubMed Web of Science ®Google Scholar
• Griesshammer M, Andreoli A, Schauer S, et al. Outcome of 121 pregnancies in patients with polycythemia vera (PV). Paper presented at: 21st EHA Annual Meeting; 2016 June 9- 12; Copenhagen, Denmark: Haematolgica.
   Google Scholar
• Taylor UB, Bardeguez AD, Iglesias N, et al. Idiopathic myelofibrosis in pregnancy: a case report and review of the literature. Am J Obstet Gynecol. 1992;167(1):38–39.
   PubMed Web of Science ®Google Scholar
• Gotic M, Cvetkovic M, Bozanovic T, et al. Successful treatment of primary myelofibrosis with thrombocytosis during pregnancy with alfa-interferon. Srpi Arh Celok Lek. 2001;129:304–308.
   PubMedGoogle Scholar
• Tulpule S, Bewley S, Robinson SE, et al. The management and outcome of four pregnancies in women with idiopathic myelofibrosis. Br J Haematol. 2008;142:480–482.
   PubMed Web of Science ®Google Scholar
• Okoli S, Wilkins B, Robinson S, et al. Diagnosis of a myeloproliferative disorder in late pregnancy. Obstet Med. 2013;6(1):26–27.
   PubMedGoogle Scholar
• Zivkovic R, Markovic O, Marisavljevic D, et al. Management of myelofibrosis during pregnancy: a case report. Vojnosanitetski Pregled. 2015;72:383–385.
   PubMed Web of Science ®Google Scholar
• Horowitz NA, Lavi N, Nadir Y, et al. Haematological malignancies in pregnancy: an overview with an emphasis on thrombotic risks. Thromb Haemost. 2016;116(4):613–617.
   PubMed Web of Science ®Google Scholar
• McNally RJ, Roman E, Cartwright RA, et al. Leukemias and lymphomas: time trends in the UK, 1984-93. Cancer causes control. 1999;10(1):35–42.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Harrison C. Essential thrombocythemia. Semin Hematol. 2005;42(4):230–238.
   PubMed Web of Science ®Google Scholar
• Andersen N, Wohlfahrt J, Christens P, et al. Maternal age and fetal loss: population based register linkage study. BMJ. 2000;320(7251):1708–1712.
   PubMedGoogle Scholar
• Schleußner E. The prevention, diagnosis and treatment of premature labor. Dtsch Ärztebl Int. 2013;110(13):227–235.
   PubMed Web of Science ®Google Scholar
• Green L, Knight M, Seeney F, et al. The epidemiology and outcomes of women with postpartum haemorrhage requiring massive transfusion with eight or more units of red cells: a national cross-sectional study. BJOG. 2016;123(13):2164–2170.
   PubMed Web of Science ®Google Scholar
• Hoagland HC, Silverstein MN. Primary thrombocythemia in the young patient. Mayo Clin Proc. 1978;53(9):578–580.
   PubMed Web of Science ®Google Scholar
• Bangerter M, Güthner C, Beneke H, et al. Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies. Eur J Haematol. 2000;65:165–169.
   PubMed Web of Science ®Google Scholar
• Chow EY, Haley LP, Vickars LM. Essential thrombocythemia in pregnancy: platelet count and pregnancy outcome. Am J Hematol. 1992;41:249–251.
   PubMed Web of Science ®Google Scholar
• Reese JA, Peck JD, Deschamps DR, et al. Platelet counts during pregnancy. N Engl J Med. 2018;379(1):32–43.
   PubMed Web of Science ®Google Scholar
• Griesshammer M, Grunewald M, Michiels JJ. Acquired thrombophilia in pregnancy: essential thrombocythemia. Semin Thromb Hemost. 2003;29:205–212.
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Kristinsson SY, Andersson TM, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30(24):2995–3001.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356–1363.
   PubMed Web of Science ®Google Scholar
• Griesshammer M, Bergmann L, Pearson T. Fertility, pregnancy and the management of myeloproliferative disorders. Baillieres Clin Haematol. 1998;11:859–874.
   PubMedGoogle Scholar
• Duley L, Henderson-Smart D, Knight M, et al. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ. 2001;322(7282):329–333.
   PubMedGoogle Scholar
• Norgard B, Puho E, Czeizel AE, et al. Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. Am J Obstet Gynecol. 2005;192(3):922–923.
   PubMed Web of Science ®Google Scholar
• Beer PA, Erber WN, Campbell PJ, et al. How I treat essential thrombocythemia. Blood. 2011;117(5):1472–1482.
   PubMed Web of Science ®Google Scholar
• Randi ML, Rossi C, Fabris F, et al. Essential thrombocythemia in young adults: treatment and outcome of 16 pregnancies. J Intern Med. 1999;246:517–518.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vanucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J. 2018;8:1–6.
   PubMed Web of Science ®Google Scholar
• Hunt BJ, Gattens M, Khamashta M, et al. Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event. Blood Coagul Fibrinolysis. 2003;14(8):735–739.
   PubMed Web of Science ®Google Scholar
• Bj S, Aw L, Mh P, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost. 1999;81(5):668–672.
   PubMed Web of Science ®Google Scholar
• Pagliaro P, Arrigoni L, Muggiasca ML, et al. Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases. Am J Hematol. 1996;53(1):6–10.
   PubMed Web of Science ®Google Scholar
• Beauverd Y, Radia D, Cargo C, et al. Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. Haematologica. 2016;101(5):e182–e184.
   PubMed Web of Science ®Google Scholar
• Sakai K, Ueda A, Hasegawa M, et al. Efficacy and safety of interferon alpha for essential thrombocythemia during pregnancy: two cases and a literature review. Int J Hematol. 2018;108(2):203–207.
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–770.
   PubMed Web of Science ®Google Scholar
• Pons JC, Lebon P, Frydman R, et al. Pharmacokinetics of interferon-alpha in pregnant women and fetoplacental passage. Fetal Diagn Ther. 1995;10:7–10.
   PubMed Web of Science ®Google Scholar
• Vantroyen B, Vanstraelen D. Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment. Acta Haematol. 2002;107(3):158–169.
   PubMed Web of Science ®Google Scholar
• Vianelli N, Gugliotta L, Tura S, et al. Interferon a2a treatment in a pregnant woman with essential thrombocythemia. Blood. 1994;83:874–875.
   PubMed Web of Science ®Google Scholar
• Milano V, Gabrielli S, Rizzo N, et al. Successful treatment of essential thrombocythemia in a pregnancy with recombinant interferon-alpha 2a. J Matern Fetal Med. 1996;5:74–78.
   PubMedGoogle Scholar
• Iki S, Usuki K, Kotaki M, et al. Successful pregnancy and delivery during alpha-interferon therapy for essential thrombocythemia. Rinsho Ketsueki. 1999;40:1201–1203.
   PubMedGoogle Scholar
• Martinelli P, Martinelli V, Agangi A, et al. Interferon alfa treatment for pregnant women affected by essential thrombocythemia: case reports and a review. Am J Obstet Gynecol. 2004;191(6):2016–2020.
   PubMed Web of Science ®Google Scholar
• Iwashita T, Fujitani M, Yamatoma Y, et al. Interferon alpha treatment of essential thrombocythemia during pregnancy. Intern Med. 2006;45:1161–1164.
   PubMed Web of Science ®Google Scholar
• Seror J, Sentilhes L, Lefebvre-Lacoeuille C, et al. Interferon-alpha for treatment of essential thrombocythemia during pregnancy: case report and review of the literature. Fetal Diagn Ther. 2009;25:136–140.
   PubMed Web of Science ®Google Scholar
• Singh N, Kumar S, Roy KK, et al. Successful maternal and fetal out come in a rare case of essential thrombocythemia with pregnancy using interferon alfa. Platelets. 2012;23:319–321.
   PubMed Web of Science ®Google Scholar
• Jayasekara WM, Abeyratne SA, Kulathilake C, et al. Successful management of a pregnancy complicated by essential thrombocythemia with pegylated interferon. Ceylon Med J. 2015;60(2):72–73.
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Katsurada T, Nakabou Y, et al. Efficacy of interferon-alpha in essential thrombocythemia during pregnancy. Ann Hematol. 2017;96(5):877–878.
   PubMed Web of Science ®Google Scholar
• Kumar AR, Hale TW, Mock RE. Transfer of interferon alfa into human breast milk. J Hum Lact. 2000;16(3):226–228.
   PubMedGoogle Scholar
• Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79(11):1130–1135.
   PubMed Web of Science ®Google Scholar
• Asano Y, Okaniwa A. In utero morphological effects of hydroxyurea on the fetal development in Sprague-Dawley rats. Jikken Dobutsu. 1987;36:143–149.
   PubMed Web of Science ®Google Scholar
• Perez-Encinas M, Bello JL, Perez-Crespo S, et al. Familial myeloproliferative syndrome. Am J Hematol. 1994;46:225–229.
   PubMed Web of Science ®Google Scholar
• Falconer J, Pineo G, Blahey W, et al. Essential thrombocythemia associated with recurrent abortions and fetal growth retardation. Am J Hematol. 1987;25:345–347.
   PubMed Web of Science ®Google Scholar
• Beard J, Hillmen P, Anderson CC, et al. Primary thrombocythemia in pregnancy. Br J Haematol. 1991;77:371–374.
   PubMed Web of Science ®Google Scholar
• Beressi AH, Tefferi A, Silverstein MN, et al. Outcome analysis of 34 pregnancies in women with essential thrombocythemia. Arch Intern Med. 1995;155(11):1217–1222.
   PubMedGoogle Scholar
• Skeith L, Carrier M, Robinson SE, et al. Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis. Blood. 2017;129(8):934–939.
   PubMed Web of Science ®Google Scholar
• Lapoirie J, Contis A, Guy A, et al. Management and outcomes of 27 pregnancies in women with myeloproliferative neoplasms. J Matern Fetal Neonatal Med. 2018;26:1–8.
   Google Scholar